Advanced search
1 file | 630.17 KB

Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis.

Filip De Maeyer (UGent) , Bruno Lapauw (UGent) , Anne Hoorens (UGent) , Anja Geerts (UGent) , Hans Van Vlierberghe (UGent) and Xavier Verhelst (UGent)
Author
Organization
Abstract
Autoimmune hepatitis (AIH) is a rare cause of chronic liver disease. The backbone of treatment is immunosuppressive medication, typically prednisolone as induction therapy and azathioprine as a maintenance therapy. Side effects of the long-term use of systemic corticosteroids are well known and have led to the use of alternative induction regimens. An attractive alternative is budesonide, a nonhalogenated glucocorticosteroid characterized by a high first-pass effect in the liver (90%), resulting in a high topical anti-inflammatory activity and a low systemic activity. It should be stressed that budesonide is contraindicated in patients with established cirrhosis with portal hypertension and portocaval shunting. In this case report, we present the first case of adrenal insufficiency following treatment with budesonide for AIH.

Downloads

  • Secondary.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 630.17 KB

Citation

Please use this url to cite or link to this publication:

Chicago
De Maeyer, Filip, Bruno Lapauw, Anne Hoorens, Anja Geerts, Hans Van Vlierberghe, and Xavier Verhelst. 2018. “Secondary Adrenal Insufficiency After Treatment with Budesonide for Autoimmune Hepatitis.” Case Reports in Gastroenterology 12 (3): 597–601.
APA
De Maeyer, F., Lapauw, B., Hoorens, A., Geerts, A., Van Vlierberghe, H., & Verhelst, X. (2018). Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis. Case reports in gastroenterology, 12(3), 597–601.
Vancouver
1.
De Maeyer F, Lapauw B, Hoorens A, Geerts A, Van Vlierberghe H, Verhelst X. Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis. Case reports in gastroenterology. 2018;12(3):597–601.
MLA
De Maeyer, Filip et al. “Secondary Adrenal Insufficiency After Treatment with Budesonide for Autoimmune Hepatitis.” Case reports in gastroenterology 12.3 (2018): 597–601. Print.
@article{8607989,
  abstract     = {Autoimmune hepatitis (AIH) is a rare cause of chronic liver disease. The backbone of treatment is immunosuppressive medication, typically prednisolone as induction therapy and azathioprine as a maintenance therapy. Side effects of the long-term use of systemic corticosteroids are well known and have led to the use of alternative induction regimens. An attractive alternative is budesonide, a nonhalogenated glucocorticosteroid characterized by a high first-pass effect in the liver (90\%), resulting in a high topical anti-inflammatory activity and a low systemic activity. It should be stressed that budesonide is contraindicated in patients with established cirrhosis with portal hypertension and portocaval shunting. In this case report, we present the first case of adrenal insufficiency following treatment with budesonide for AIH.},
  author       = {De Maeyer, Filip and Lapauw, Bruno and Hoorens, Anne and Geerts, Anja and Van Vlierberghe, Hans and Verhelst, Xavier},
  issn         = {1662-0631},
  journal      = {Case reports in gastroenterology},
  number       = {3},
  pages        = {597--601},
  title        = {Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis.},
  url          = {http://dx.doi.org/10.1159/000492204},
  volume       = {12},
  year         = {2018},
}

Altmetric
View in Altmetric